Skip to main content
Terug
CASBF logo

CanSino Biologics Inc.

Datakwaliteit: 100%
Oversold
CASBF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 3,86
€ 0,00 (0,00%)
Marktkapitalisatie: 1,35B
Dagbereik
€ 3,86 € 4,10
52-Weeksbereik
€ 3,20 € 6,99
Volume
1.200
50D / 200D Gem.
€ 4,29 / € 4,91
Vorige Slotkoers
€ 3,86

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 49,7 0,4
P/B 0,3 2,9
ROE % 0,5 3,8
Net Margin % 2,6 3,9
Rev Growth 5Y % -29,9 10,0
D/E 0,4 0,2

Belangrijkste Punten

Revenue declined -29,86% annually over 5 years
ROE of 0,53% is below average
Debt/Equity of 0,41 — conservative balance sheet
Negative free cash flow of -626,43M
P/E of 49,66 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 55,98%

Groei

Revenue Growth (5Y)
-29,86%
Revenue (1Y)26,12%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
0,53%
ROIC0,25%
Net Margin2,61%
Op. Margin2,24%

Veiligheid

Debt / Equity
0,41
Current Ratio2,42
Interest Coverage0,00

Waardering

P/E Ratio
49,66
P/B Ratio0,27
EV/EBITDA77,49
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 26,12% Revenue Growth (3Y) 73,61%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -29,86% Earnings Growth (5Y) -65,49%
Profitability
Revenue (TTM) 1,04B Net Income (TTM) 27,15M
ROE 0,53% ROA 0,34%
Gross Margin 0,00% Operating Margin 2,24%
Net Margin 2,61% Free Cash Flow (TTM) -626,43M
ROIC 0,25% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,41 Current Ratio 2,42
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 49,66 P/B Ratio 0,27
P/S Ratio 1,30 PEG Ratio -2,89
EV/EBITDA 77,49 Dividend Yield 0,00%
Market Cap 1,35B Enterprise Value 1,81B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,04B 824,88M 345,18M 1,03B 4,30B
Net Income 27,15M -378,88M -1,48B -909,43M 1,91B
EPS (Diluted) 0,11 -1,53 -6,01 -3,69 7,74
Gross Profit 0,0 580,45M -876,02M -186,61M 3,00B
Operating Income 23,30M -403,39M -2,04B -1,37B 1,94B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 7,96B 9,32B 11,47B 11,87B 6,75B
Total Liabilities 3,05B 4,03B 4,22B 3,33B 677,22M
Shareholders' Equity 4,91B 5,27B 6,75B 8,00B 6,07B
Total Debt 2,01B 2,70B 2,70B 1,37B 142,54M
Cash & Equivalents 1,56B 2,05B 3,39B 5,46B 4,45B
Current Assets 4,28B 5,18B 7,73B 9,29B 5,42B
Current Liabilities 1,77B 2,59B 2,94B 2,87B 412,85M